TCT-172 Aspirin monotherapy after left atrial appendage occlusion with the Amplatzer Cardiac Plug: results from the ACP Study Group Registry  by Tzikas, Apostolos et al.
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: LAA closure with the WATCHMAN reduced bleeding compared with
warfarin after post-procedural adjunctive therapy was completed. This should be
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Background: To investigate the safety and efﬁcacy of left atrial appendage occlusion
(LAAO) with the Amplatzer Cardiac Plug (ACP) for stroke prevention in patients with
atrial ﬁbrillation (AF).
Methods: Data from consecutive patients treated in 22 centers were collected. Patients
who underwent successful single LAAO and who were on aspirin monotherapy or no
therapy at last follow-up were included in the study.
Results: A total of 627 patients (age 758 years) fulﬁlled the inclusion criteria. Of those,
579were on aspirin (92%) and 48 received no treatment (8%) at last follow-up. Themean
CHA2DS2-VASc score was 4.41.5 (annual risk of thromboembolism ¼ 5.62.7%),
and the mean HASB-LED Score was 3.21.2 (annual risk of major bleeding ¼
5.73.9%). There were 3 strokes (0.5%), 1 transient ischemic attack (TIA) (0.2%), and 8
major bleedings (1.3%) in the periprocedural period. The median (IQR) follow-up was
16.2 (9.7-26.2) months, accumulating 981 patient years. A total of 21 deaths were re-
ported during follow-up, which were not reported as device related. There were 3 strokes
(0.5%), 6 TIAs (1.0%), and 5 major bleedings (0.8%) during follow-up. The annual rate
of systemic thromboembolism was 1.33% (13/981 patient-years), which is a 76.4% risk
reduction compared to the annual predicted rate. The annual rate of major bleeding was
1.33% (13/981 patient-years), which is a 76.5% risk reduction.
Conclusions: In this multicenter study, LAAO with the ACP and aspirin or no therapy
at follow-up was effective in preventing thromboembolism, and was combined with a
reduction of major bleeding events.
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Background: Percutaneous left atrial appendage (LAA) occlusion is commonly
performed under general anesthesia and trans-esophageal echocardiography (TEE)
guidance. Intra-cardiac echocardiography (ICE) offers several advantages over TEE
for procedural guidance; however experience is limited with LAA occlusion. In
previous reports of LAA closure under ICE guidance, ICE was performed from theJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Leright atrium or coronary sinus where complete visualization of the LAA anatomy is
uncertain. We sought to evaluate the feasibility, efﬁcacy and safety of LAA occlusion
using ICE guidance from the left atrium (LA).
Methods: Twenty-three patients with AF, signiﬁcant risk for stroke and long-term
contra-indication for anticoagulation underwent LAA closure with the Amplatzer Car-
diacPlugTM(St.JudeMedical Inc.) under conscious sedation and ICEguidance.The ICE
catheter and ACP delivery sheath were advanced into the LA through separated trans-
septal punctures. Baseline patient characteristics, procedural and follow-up data were
prospectively recorded. Clinical and TEE follow-up was done at 3 months after the
procedure. Procedural successwas deﬁned as the implantation of the closure device at the
intended delivery site with adequate (grade 3 ormore by angiography and ICE) occlusion
Results: Procedural success was achieved in 22 of 23 patients (96%) with a mean
procedural time of 105 +/- 27 minutes; challenging anatomy was the reason of failure.
Median hospital stay was 1 day. No major procedural complication occurred however
two patients died during the follow up period. In both cases, death was not related to the
procedure or device. At 3-months, total LAA occlusion was observed in the 17 device-
recipient survivors who had completed TEE follow-up. In all cases, ICE provided
adequate procedural guidance, closure assessment and LAA and device visualization,
including their relation with adjacent structures. Best imaging of the LAAwas available
with the ICE catheter placed in a mid-LA location or just above the mitral plane.
Conclusions: Initial experience suggests that LAA occlusion with the Amplatzer
Cardiac PlugTM under ICE guidance from the left atrium in conscious patients is
feasible, reproducible and safe.
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Background: Left atrial appendage (LAA) device imaging after percutaneous closure
for atrial ﬁbrillation is important to assess for residual leak, device-associated thrombus,
device positioning, surrounding structures, and pericardial effusion. Cardiac computed
tomography angiography (CCTA) is well suited to assess these features non-invasively.
Methods: We report our pilot consecutive series of follow-up CCTA after LAA
closure with the Amplatzer Cardiac Plug (ACP), Amulet, or Watchman devices, at
Vancouver General Hospital. Patients were treated with aspirin indeﬁnitely, and
clopidogrel for 1-3 months following LAA closure. Transthoracic echocardiograms
were routinely performed at 1 month and CCTA at 1-6 months post-procedure for
clinical surveillance in this series of patients. Prospective cardiac-gated CCTA were
performed with Toshiba 320-slice or Siemens 2nd generation 128-slice dual source
scanners, and images were interpreted with the Vitrea software. GFR < 40 was an
exclusion. We assessed for atrial-side device thrombus, residual contrast leak into the
LAA, pericardial effusion, and device dimensions.
Results: Twenty-ﬁve patients underwent CCTA at a mean of 157  143 days
following LAA closures (13 ACP, 8 Amulet, and 4 Watchman). Average age was
75.5  9.8 years, and CHADS2 score was 3.2  1.3. All patients had contraindica-
tions to anticoagulation for atrial ﬁbrillation, and were treated with dual antiplatelet
therapy post-procedure. All devices were visualized within the LAA on CCTA. No
pericardial effusion was seen on CCTA follow-up. Only one patient had thrombus on
the atria-side of the device. Sixty-ﬁve percent had residual leak into the LAA on
CCTA at follow-up. Device measurements on CCTA and correlation to TEE mea-
surements post-procedure and device dimensions will be presented.
Conclusions: CCTA is a useful non-invasive imaging test for clinical surveillance
after percutaneous LAA closure. Assessments of device position, atrial-side thrombus,
pericardial effusion, and residual patency into the LAA are well visualized on CCTA.
However, residual LAA patency is seen frequently on CCTA, and correlation to the
degree of TEE residual leak should be further explored.
TCT-175
Preclinical Study of Novel Generation of Watchman for Left Atrial Appendage
Occlusion
Dongming Hou1, Brian Tischler1, Pﬂugfelder Alex1, Vijay Koya1, Mindy Jedlicki1,
Coleman Holly1, Jason A. Kilvington1, Barbara A. Huibregtse1
1Boston Scientiﬁc Corporation, Marlborough, MA
Background: WATCHMAN is the most studied LAA device clinically with >2000
implantations and >5000 patient-years of follow-up. Currently, a new generation of
Watchman has been designed to further improve implant performance. Similar to the
current generation (CG-WM), the next generation (NG-WM) also has a self-expanding
nitinol frame structure, which is covered with a permeable polyester fabric membrane and
deployed using a 12F delivery systemwith a 14F access sheath. The key design changes in
theNG-WMinclude18struts (vs. 10 inCG-WM), anatraumatic closeddistal end (vs. open
end inCG-WM), and reduced length of theNG-WM.TheNG-WMcanbe redeployedafter
either full or partial recapture. In contrast, the CG-WMhas to be replaced if a full recapture
is needed. The present study is aimed to test the NG-WM device in a canine LAAmodel.
Methods: A total of 14 dogs were used in the study. Under TEE at 0, 45, 90 and 135
views and x-ray guidance, both CG-WM and NG-WM were appropriately sized to be
10-20% larger than the LAA ostium.ft Atrial Appendage Exclusion B51
